<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01947894</url>
  </required_header>
  <id_info>
    <org_study_id>A6281313</org_study_id>
    <secondary_id>SWEGHO</secondary_id>
    <nct_id>NCT01947894</nct_id>
  </id_info>
  <brief_title>A Prospective Non-Interventional Study Protocol With Primary Data Collection - Assessment Of The Long Term Treatment Outcomes Of Genotropin Treatment In Growth Hormone Deficiency (GHD) Patients</brief_title>
  <official_title>Swegho - A Prospective Non Interventional Study Protocol With Primary Data Collection - Assessment Of The Long Term Treatment Outcomes Of Genotropin Treatment In Ghd Patients In Sweden</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the long term treatment outcomes of Growth Hormone
      treatment in patients who are prescribed and treated with Genotropin. Also, plan to determine
      the relationships between clinical status, dosage schedule and response to Genotropin
      treatment.

      This study will also contribute to our knowledge of adult Growth Hormone Deficiency,
      including transition period in Childhood Onset Growth Hormone Deficiency and its treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients within inclusion criteria are asked to participate in the study.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 20, 2013</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>This Non-Interventional study does not include pre-specified endpoints, but collects information from adult subjects recieving Genotropin treatment in a real world clinic setting.</measure>
    <time_frame>no time frame</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">372</enrollment>
  <condition>Growth Hormone Deficiency</condition>
  <arm_group>
    <arm_group_label>Adult Growth Hormone deficient Patients</arm_group_label>
    <description>Patients with GHD on Genotropin® replacement therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non Interventional Study</intervention_name>
    <description>Non Interventional Study</description>
    <arm_group_label>Adult Growth Hormone deficient Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients wiht Growth Hormone Deficiency
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients of 18 years of age and above and fulfilling one of the three
             alternatives a-c below;

               1. Newly diagnosed with GHD according to the current medical standard.

               2. Diagnosed with GHD before 2013 and previously treated with Genotropin and
                  followed in KIMS®.

               3. Transition patients diagnosed with CO-GHD before 2013.

          -  Prescribed Genotropin at the time of inclusion.

          -  Evidence of a personally signed and dated informed consent document indicating that
             the patient (or a legally acceptable representative) has been informed of all
             pertinent aspects of the study.

        Exclusion Criteria:

          -  Patients who participate in any concurrent clinical interventional trial where a
             non-authorized or authorized study medication is used, during their participation in
             Swedish KIMS® Xtended. Concurrent studies which do not include any study
             interventional items (whether medications or devices) are allowed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vastra Gotalands Regionen</name>
      <address>
        <city>Skovde</city>
        <state>Skaraborg</state>
        <zip>541 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landstinget Dalarna</name>
      <address>
        <city>Falun</city>
        <zip>791 82</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University hospital</name>
      <address>
        <city>Goteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Hospital/ Department of Medicine</name>
      <address>
        <city>Kristianstad</city>
        <zip>291 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitetssjukhuset, EM-kliniken</name>
      <address>
        <city>Linköping</city>
        <zip>581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ljungby Lasarettet</name>
      <address>
        <city>Ljungby</city>
        <zip>341 82</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital SUS</name>
      <address>
        <city>Malmo</city>
        <zip>205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landstinget i Stockholms Lan</name>
      <address>
        <city>Stockholm</city>
        <zip>118 83</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset, Kliniken for Endokrinologi</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiska sjukhuset / Medicincentrum, Diabetes- och Endokrinsektionen</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landstinget i Jonkopings Lan</name>
      <address>
        <city>Varnamo</city>
        <zip>331 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicinkliniken, Centrallasarettet Vaxjo</name>
      <address>
        <city>Vaxjo</city>
        <zip>351 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6281313&amp;StudyName=A%20Prospective%20Non-Interventional%20Study%20Protocol%20With%20Primary%20Data%20Collection%20-%20%20Assessment%20Of%20The%20Long%20Term%20Treatment%20Outcomes%20Of%20Genotr</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2013</study_first_submitted>
  <study_first_submitted_qc>September 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2013</study_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocrine System Diseases</mesh_term>
    <mesh_term>Dwarfism, Pituitary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

